During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

Suggested remit: To appraise the clinical and cost effectiveness of Belzutifan + Lenvatinib within its marketing authorisation for treating renal cell carcinoma.

The median progression-free survival was 30.3 months, and the median overall survival was not reached. The combination of belzutifan and cabozantinib has demonstrated “promising” antitumor ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

At the final analysis, the coprimary endpoint of overall survival was not met. Topline data were announced from a phase 3 trial evaluating pembrolizumab (Keytruda ®) plus lenvatinib (Lenvima ...

Up to 25% of PPGL cases are metastatic at diagnosis. Certain von Hippel-Lindau (VHL) disease-associated tumors WELIREG (belzutifan) is indicated for the treatment of adult patients with von ...